The six lanes you actually have
Forget the marketing pages. There are six legal pathways to GLP-1 weight loss in May 2026, and the prices range by an order of magnitude depending on which one fits your situation:
- Brand-name Wegovy or Ozempic via insurance — cheapest if you can clear the prior-authorization hurdle
- Compounded semaglutide via a licensed pharmacy — lowest cash-pay entry; still legal pending the FDA's proposed rule
- NovoCare cash-pay — Novo Nordisk's direct self-pay program for Wegovy
- LillyDirect Zepbound vials — switch molecule to tirzepatide; the cheapest brand-name cash-pay path
- Telehealth + brand-name GLP-1 — licensed-clinician program prescribing branded medication
- Brand-name Wegovy at list price — the option to avoid unless nothing else fits
We'll walk each one with the actual numbers. Skip ahead to the summary table if you want the comparison view first.
Lane 1: Wegovy or Ozempic via insurance
If you have commercial insurance coverage
$25–$100 / month
Depending on your plan's tier and any manufacturer savings card stacking. Plans with a $25-$50 copay tier for specialty drugs land at the low end; high-deductible plans where you pay the negotiated rate until you hit the deductible can be much higher early in the year.
How to check fast: Call the member services number on the back of your insurance card. Ask specifically: “Is Wegovy on formulary? What's the prior authorization requirement? Is there a maximum quantity per fill?” Don't trust the formulary website — they're often out of date by months.
What it doesn't include: Most insurance plans require a documented BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity like high blood pressure or pre-diabetes) for Wegovy. Ozempic is covered for type 2 diabetes only. Prior authorization typically requires your prescriber to submit chart notes documenting prior weight-loss attempts (failed diet/exercise within 6 months). Expect the PA process to take 1-3 weeks the first time; renewals are faster.
If your insurance won't cover: Don't give up at "denied." Manufacturer copay cards (Novo Nordisk's WeGoTogether card for Wegovy) can reduce copays even on covered plans. And for plans that exclude weight-loss drugs entirely, ask your prescriber to bill for an indication you do have (type 2 diabetes or cardiovascular risk reduction) if clinically appropriate. This is a real practice, not a workaround.
Lane 2: Compounded semaglutide via a licensed pharmacy
The cash-pay lane that's been keeping GLP-1s accessible since 2022. Compounded semaglutide is made by U.S.-licensed compounding pharmacies under Section 503A or 503B of the Food, Drug, and Cosmetic Act. Compounded medications are not FDA-approved — they're prepared by licensed pharmacies under state regulation, not federal approval.
The FDA's April 30, 2026 proposed rule would close the 503B mass-compounding pathway if finalized. It is not yet final. Public comment runs through June 29, 2026; industry analysts expect the earliest implementation in Q3-Q4 2026. As of May 2026, compounded semaglutide remains legally available from licensed providers — and the 503A patient-specific pathway is not affected by the proposal regardless.
Recommended · LegitScript-certified, 50 states, transparent pricing
LegUpRx — sublingual semaglutide
$174/mo · $449/3mo · $749/6mo
LegUpRx (Leg Up Recovery) operates the compounded model the way it was designed: licensed prescribers in all 50 states, LegitScript-certified pharmacy network, retail prices published before intake. The sublingual formulation is the lowest-cost compounded GLP-1 entry point we've found. Three-month and six-month tiers reduce the per-month rate to $150 and $125 respectively.
Also at LegUpRx (compounded): Injectable semaglutide with additives $299/month. Injectable tirzepatide with additives $499/month. Microdose semaglutide+B12 $199/month. Full LegUpRx weight-loss catalog.
Check LegUpRx eligibility →Promo-driven · DTC consumer brand · $200 off first month
Sprout Health — compounded semaglutide and tirzepatide
$200 off first month (post-quiz pricing)
Sprout Health (joinsprouthealth.com) runs the consumer-DTC version of the compounded model — 40,000+ patient testimonials, no separate consult fees, dose-escalation price lock, free shipping. Pricing is revealed after a two-minute eligibility quiz; the headline promo is $200 off your first month. Sprout sells both compounded semaglutide and compounded tirzepatide.
If you respond better to consumer-brand polish than to a pharmacy-network model, this is your lane. If you want price transparency upfront, LegUpRx publishes prices before intake; Sprout reveals after.
See Sprout Health's offer →What compounded options don't include: the FDA's safety and effectiveness review that branded medications go through. Compounded products are formulated by licensed pharmacies under state regulation; they're not federally approved as safe and effective. The FDA has documented over 455 adverse-event reports tied to compounded semaglutide as of early 2025, many involving multidose-vial dosing errors. The risk profile is real but mostly tied to unlicensed gray-market sellers, not LegitScript-certified pharmacies like LegUpRx or established DTC programs like Sprout Health. Talk to your prescriber.
Lane 3: NovoCare cash-pay (Wegovy direct)
No affiliate revenue · the cheapest brand-name cash-pay for Wegovy
NovoCare — Wegovy self-pay program
~$499 / month
Novo Nordisk's direct-to-patient self-pay program (Source: novocare.com). For uninsured patients or those whose insurance excludes weight-loss medication. Requires a prescription from any licensed prescriber — not just a Novo-affiliated clinician. The medication ships from a partner pharmacy.
What it includes: The medication itself, at one fixed cash price. You need to handle the prescription separately (your PCP, an endocrinologist, or a telehealth provider can prescribe). You also handle any side-effect monitoring and dose titration outside the program.
How to use it: Get a prescription from any U.S.-licensed prescriber, then route the fill through NovoCare. Some telehealth providers will write the prescription specifically for NovoCare fulfillment if you ask — saves you the markup of a telehealth program that bundles medication.
Lane 4: LillyDirect Zepbound vials (switching molecule)
No affiliate revenue · the cheapest brand-name cash-pay overall
LillyDirect — Zepbound vials (tirzepatide)
$349/mo (2.5mg) → $549/mo (10mg+)
Eli Lilly's direct-to-patient cash program for tirzepatide (Source: lillydirect.com). Same drug class as semaglutide, similar or stronger weight-loss outcomes in head-to-head trials (Source: NEJM, SURMOUNT-5, 2024 — tirzepatide showed greater mean weight reduction than semaglutide at 72 weeks).
The catch: Vials, not pre-filled pens. You self-draw the dose with a syringe each week. It's a one-time skill to learn (the company provides instructions and video), but it's a meaningful difference from the convenience of a Wegovy or Ozempic pen.
Lane 5: Telehealth + brand-name GLP-1
For patients who want brand-name + bundled clinical service
MEDVi — physician-supervised brand-name program
$450–$700 / month all-in
MEDVi runs the FDA-approved brand-name telehealth model: licensed clinicians, branded Wegovy / Ozempic / Mounjaro / Zepbound dispensed by accredited pharmacies. The all-in cost typically lands in the $450-$700 range — manufacturer cash price plus a clinical-services fee. More than LegUpRx's compounded options or LillyDirect's direct program, but the program manages the prescription, the dose titration, and the side-effect monitoring as one bundle.
When does this make sense? If you want brand-name FDA-approved medication, don't have an existing prescriber relationship, and value a single point of contact for the full program rather than coordinating across an insurance prescription + manufacturer cash program.
Check MEDVi eligibility →Lane 6: Brand-name Wegovy at list price
The lane to avoid unless nothing else fits
Wegovy at U.S. list price
~$1,349 / month
The U.S. wholesale acquisition cost for a full month of Wegovy is approximately $1,349 (Source: Novo Nordisk's published WAC pricing, 2025). This is what an uninsured patient pays at a retail pharmacy without using NovoCare or any savings program. There's essentially no reason to pay this price — NovoCare's $499/month self-pay is from the same manufacturer, same product, lower price. If a pharmacy or telehealth program quotes you anything near $1,349, walk away.
The twelve-month all-in math, side by side
| Lane | Monthly | 12-month all-in | Affiliate |
|---|---|---|---|
| Wegovy via insurance (good plan) | $25–$100 | $300–$1,200 | None |
| LegUpRx sublingual semaglutide (compounded) | $174 (1mo) / $749 (6mo) | ~$1,500 | Yes |
| LegUpRx microdose semaglutide+B12 (compounded) | $199 | ~$2,400 | Yes |
| LegUpRx injectable semaglutide (compounded) | $299 | ~$3,600 | Yes |
| Sprout Health compounded | $200 off month 1; post-quiz pricing | ~$2,000–$3,500 | Yes |
| LillyDirect Zepbound vials (2.5–5mg) | $349–$499 | ~$5,000 | None |
| NovoCare Wegovy self-pay | ~$499 | ~$6,000 | None |
| MEDVi brand-name telehealth program | $450–$700 | ~$5,400–$8,400 | Yes |
| Wegovy at list price (avoid) | ~$1,349 | ~$16,000 | None |
| Cheapest legal cash-pay path: | $174/mo (LegUpRx sublingual) | ~$1,500/year | — |
Three patterns to notice:
- Insurance is the single biggest savings if available. The cost gap between a covered plan and any cash-pay option is $3,000-$5,000/year. Thirty minutes on the phone with your insurer is the highest-value single action you can take.
- Compounded is roughly half the cost of branded cash-pay. $1,500-$3,600/year compounded vs. $5,000-$6,000/year branded cash-pay. Whether the savings is worth the trade-off (no FDA approval, smaller safety dataset, regulatory uncertainty pending the proposed rule) is a decision for you and your prescriber.
- Telehealth + brand-name is the most expensive bundle in most cases. It's worth it if you value the bundled clinical service and don't have an existing prescriber. It's not worth it if your PCP will prescribe and you can route through NovoCare or LillyDirect directly.
What the price doesn't include
Provider pages quote the medication price, but the all-in cost has more in it. Watch for these:
- Intake or consultation fees — some programs charge a separate $50-$150 one-time fee on top of the monthly price.
- Dose-escalation surcharges — the semaglutide titration ladder goes 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over months. Some programs raise the monthly price as the dose escalates; others (Sprout Health explicitly, LegUpRx implicitly) hold the price flat. Always ask.
- Shipping fees and cold-chain surcharges — injectable GLP-1s require refrigerated shipping. Most reputable programs include this; some surprise-bill for it.
- Side-effect-related lab tests — if you develop GI symptoms, fatigue, or other side effects, your prescriber may order labs (CBC, metabolic panel, fasting glucose, lipid panel, occasionally amylase/lipase). If your insurance doesn't cover these, expect $50-$200 per panel.
- Pause and cancellation fees — some subscription programs charge fees to pause or cancel. Sprout Health says “no contracts” in their marketing; LegUpRx doesn't auto-renew without your confirmation on the multi-month tiers. Read the fine print before committing to a 6-month plan.
- The cost of side effects you handle outside the program — OTC anti-nausea (ondansetron, ginger), fiber supplements, electrolyte drinks. Small money but real.
What we'd actually do
In order, lowest-effort-highest-leverage:
- Spend 30 minutes calling your insurer. If Wegovy is covered with any plan-level path — even with prior-authorization hurdles — do this. The cost difference is $3,000-$5,000/year. We don't earn anything on this lane and we still tell you to do it first.
- If insurance won't cover, start with LegUpRx's sublingual semaglutide at $174/month. Lowest legitimate cash entry point. LegitScript-certified. Survives the FDA's proposed rule under the 503A patient-specific pathway. We earn a referral fee if you enroll; we recommend it anyway because nothing else hits this price with this level of credentialing.
- If you want injectable, LegUpRx's injectable semaglutide w/ additives is $299/month or click here. Same pharmacy, same prescriber framework, injectable delivery. If you want a consumer-DTC experience with a $200-off promo, Sprout Health is the other compounded lane.
- For brand-name cash-pay, default to LillyDirect Zepbound vials at $349/month. Same drug class, similar or stronger outcomes than semaglutide. Lilly is the manufacturer — no markup layer. We don't earn anything on LillyDirect; we still recommend it.
- Skip telehealth markups if you have a prescriber. Telehealth + brand-name is $450-$700/month all-in, while NovoCare or LillyDirect with your existing PCP's prescription is $349-$499. The bundle is worth it only if you don't have a prescriber and value the single-vendor convenience.
- Avoid the list price. $1,349/month exists as a number on a price list, not as a sensible option.
- Avoid “research peptide” sites and offshore vendors. The savings are real, the safety floor is gone. We covered this in detail in our FDA-ban explainer.
Frequently asked questions
What's the cheapest legal way to get semaglutide in 2026?
With insurance covering Wegovy or Ozempic: typical copay is $25 to $100/month. Without insurance: compounded sublingual semaglutide via LegUpRx starts at $174/month. The cheapest brand-name cash-pay is LillyDirect's Zepbound vials at $349/month (tirzepatide, the related GLP-1 molecule). Avoid gray-market peptide vendors; the savings aren't worth the safety risk.
How much does Wegovy cost without insurance?
List price is approximately $1,349/month. Novo Nordisk's NovoCare self-pay program reduces this to roughly $499/month for cash-pay patients. Most people should not pay list price unless they have no other option.
Is compounded semaglutide still legal?
Yes as of May 2026. The FDA's April 30, 2026 proposed rule would close the 503B mass-compounding pathway if finalized, but it remains a proposal with public comment open through June 29, 2026. Licensed 503A compounding pharmacies continue dispensing compounded semaglutide for patient-specific clinical need. See our FDA-ban explainer for the full regulatory detail.
What's included in the monthly price?
It varies by provider. Manufacturer cash-pay (NovoCare, LillyDirect) includes the medication only — you handle the prescription and clinical follow-up separately. Telehealth programs bundle medication, clinician review, and prescription. Compounded programs typically include medication, clinician review, and shipping, with no separate consult fee. Always confirm whether intake fees, dose-escalation surcharges, or pause fees apply.
Does insurance cover Wegovy in 2026?
Sometimes. Large-employer commercial plans increasingly cover it with BMI-based criteria. Medicare Part D does not cover anti-obesity medications. Medicaid varies by state with strict prior authorization. Call your insurer and ask: "Is Wegovy on formulary? What's the PA requirement?"
Is tirzepatide cheaper than semaglutide?
On manufacturer cash-pay, yes. LillyDirect Zepbound vials start at $349/month vs. NovoCare Wegovy at ~$499/month. Compounded tirzepatide via LegUpRx is $499/month, modestly higher than compounded semaglutide. Insurance copays for both are typically similar when covered.
What hidden costs should I expect?
Watch for: separate intake or consultation fees ($50-$150 one-time), dose-escalation surcharges (some providers raise price as dose increases), shipping fees, side-effect-related lab tests ($50-$200 per panel if not covered), and pause or cancellation fees on subscription programs.
How long until I see results?
The clinical timeline is roughly 90 days for meaningful weight loss to begin, with continued loss over 12-18 months per the STEP trial data (Source: NEJM, STEP-1, 2021). Most patients quit at week 6 because of side effects or impatience. Plan the budget for 6 months minimum to know whether the medication is working.
Sources
- Novo Nordisk — NovoCare Wegovy self-pay program (novocare.com)
- Eli Lilly — LillyDirect Zepbound vial program (lillydirect.com)
- Novo Nordisk WAC pricing — Wegovy list price, 2025
- New England Journal of Medicine — STEP-1 trial (2021) and 2-year extension data (2022)
- New England Journal of Medicine — SURMOUNT-5 (2024), tirzepatide vs. semaglutide head-to-head
- U.S. Food and Drug Administration — Drug Shortages Database (semaglutide and tirzepatide status, 2024-2025)
- U.S. Food and Drug Administration — 503B bulks list proposed exclusion of semaglutide, tirzepatide, liraglutide (April 30, 2026)
- LegitScript pharmacy certification — LegUpRx (Leg Up Recovery) status
Prices change. We update this page when manufacturer programs adjust pricing or new lanes emerge. Spot something out of date? Email [email protected].